These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30547812)

  • 1. Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review.
    Jung JY; Kim MY; Suh CH; Kim HA
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):79. PubMed ID: 30547812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
    Alten R; Maleitzke T
    Ann Med; 2013 Jun; 45(4):357-63. PubMed ID: 23650978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chinese expert consensus on off-label use of Tocilizumab in rheumatic diseases].
    Committee of Chinese Primary Health Care Foundation for Rheumatologists and Immunologists
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(25):2308-2322. PubMed ID: 38951103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting interleukin-6 in pediatric rheumatic diseases.
    De Benedetti F
    Curr Opin Rheumatol; 2009 Sep; 21(5):533-7. PubMed ID: 19593141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Herlin T
    Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].
    Iking-Konert C; Bartz-Bazzanella P; Falagan D; Hofman MW; Schwarting A; Dörner T
    Z Rheumatol; 2014 Apr; 73(3):269-76. PubMed ID: 24166363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
    Tanaka T; Kishimoto T
    Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases.
    Ding C; Jones G
    Rev Recent Clin Trials; 2006 Sep; 1(3):193-200. PubMed ID: 18473972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab for the treatment of juvenile idiopathic arthritis.
    Decelle K; Horton ER
    Ann Pharmacother; 2012 Jun; 46(6):822-9. PubMed ID: 22589451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
    Yokota S; Kishimoto T
    Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.
    Yokota S; Miyamae T; Imagawa T; Katakura S; Kurosawa R; Mori M
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):231-8. PubMed ID: 16129907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 20. Is tocilizumab an option for the treatment of arthritis?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Aug; 9(11):2009-13. PubMed ID: 18627338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.